Pharmacy Times February 2009


Drug Interactions: Insights and Observations


Drug Transporters: The Final Frontier for Drug Interactions. Part 2


John R. Horn, PharmD, FCCP and Philip D. Hansten, PharmD




1.     Maeda A. Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells. Eur J Pharmacol. 2008;596:166-72.

2.     Regazzi MB et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc. 1993;25:2732-34.

3.     Muck W et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporin-treated kidney transplant recipients. Clin Pharm Ther. 1999;65:251-61.

4.     Griffith RS et al. Effect of probenecid on the blood levels and urinary excretion of cefamandole. Antimicrob Agents Chemother. 1977;11:809-12.

5.     Kimura H et al. Metformin isa superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005;20:379-86.

6.     Somogyi A et al. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol.1987;23:545-51.

7.     Wang ZJ et al. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics. 2008;18:637-45.

8.     Windle J et al. Pharmacokinetic and electrophysiologic interaction of amiodarone and procainamide. Clin Pharmacol Ther. 1987,41:603-10.

9.     Bauer LA et al. Levofloxacin and ciprofloxacin decrease procainamide and n-acetylprocainamide renal clearances. Antimicrob Agents Chemother. 2005;49:1649-51.

10.  Somogyi A et al. Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. Eur J Clin Pharmacol. 1983;25:339-45.